DMRA · Damora Therapeutics, Inc. · Debt
$28.10
+1.26 (+4.69%)
At close · Sep 11
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Market Cap
$1.73B
Shares
61.74M
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Key facts
CIK
1800315
CUSIP
G2646Y104
13F (30d)
52 filings
52 filers
Visit website
Investor relations